Home/ Peptides/ AOD-9604

AOD-9604

Weight Loss · Metabolism Subcutaneous Injectable

AOD-9604 is a fragment of growth hormone responsible specifically for fat metabolism — without the muscle, glucose, or growth effects of full HGH. It's a useful adjunct for targeted fat loss, particularly stubborn adipose tissue, and often layered alongside GLP-1 therapy.

Best for: Localized fat loss support, adjunct to GLP-1 therapy, clients wanting targeted metabolic support.

Book Consult→ Get discounts with memberships →
Lab-guided protocolsPersonalized dosingProvider-led oversightIn-clinic & telehealth Lab-guided protocolsPersonalized dosingProvider-led oversightIn-clinic & telehealth
Frequently Asked
What clients want to know about AOD-9604

The questions, answered.

  • Targeted fat metabolism without GH's other effects.
  • Useful adjunct to GLP-1 therapy for breaking through plateaus.
  • Does not affect blood glucose — safe in pre-diabetics.
  • Minimal side-effect profile compared to full GH.
  • Supports stubborn adipose areas traditionally resistant to diet.
  • No appetite suppression — useful when you want fat loss without GI side effects.
  • Lipolysis stimulation: increases breakdown of stored fat.
  • Inhibits lipogenesis: reduces new fat storage.
  • No effect on IGF-1 or glucose — narrow mechanism of action.
  • Stimulates beta-oxidation in fat cells.
  • Weeks 1–2: Subtle softening of stubborn fat areas; no appetite change.
  • Weeks 4–6: Measurable changes in body composition where dosed appropriately.
  • Weeks 8–12: Body composition gains consolidate; often used in cycles.
  • Mild injection-site reactions.
  • Headache or transient fatigue early in protocol.
  • Minimal compared to full HGH or aggressive GLP-1 dosing.
  • Best as a layered adjunct rather than standalone weight-loss agent.
  • Pair with strength training to drive lean mass preservation.
  • Hydrate well to support fat metabolism byproducts.
  • Reassess at 8–12 weeks to confirm objective effect.
  • Pregnancy or breastfeeding.
  • Known peptide hypersensitivity.
  • Active malignancy without provider oversight.
Important Note The FDA's position on peptides continues to evolve. Availability of specific compounds may change, and not all peptides discussed are currently offered at every visit. Book a consultation with our provider team to discuss your goals, current options, and what's appropriate for you.
Related Protocols
Often paired or layered alongside AOD-9604

Layered with intention.

Weight Loss · Metabolism
Tirzepatide
GLP-1 / GIP Dual Agonist
Weight Loss · Metabolism
Retatrutide
Triple Agonist (Investigational)
Repair & Recovery
BPC-157
Body Protective Compound
— Begin

Precision protocols.
Designed around you.

Every TAI peptide protocol is lab-guided and provider-led. Start with biomarkers, design around your goals, refine at intervals. Available in-clinic and via telehealth.

Book Consult→ Membership pricing →